Breast carcinoma cells in primary tumors and effusions have different gene array profiles.
The detection of breast carcinoma cells in effusions is associated with rapidly fatal outcome, but these cells are poorly characterized at the molecular level. This study compared the gene array signatures of breast carcinoma cells in primary carcinomas and effusions. The genetic signature of 10 primary tumors and 10 effusions was analyzed using the Array-Ready Oligo set for the Human Genome platform. Results for selected genes were validated using PCR, Western blotting, and immunohistochemistry. Array analysis identified 255 significantly downregulated and 96 upregulated genes in the effusion samples. The majority of differentially expressed genes were part of pathways involved in focal adhesion, extracellular matrix-cell interaction, and the regulation of the actin cytoskeleton. Genes that were upregulated in effusions included KRT8, BCAR1, CLDN4, VIL2, while DCN, CLDN19, ITGA7, and ITGA5 were downregulated at this anatomic site. PCR, Western blotting, and immunohistochemistry confirmed the array findings for BCAR1, CLDN4, VIL2, and DCN. Our data show that breast carcinoma cells in primary carcinomas and effusions have different gene expression signatures, and differentially express a large number of molecules related to adhesion, motility, and metastasis. These differences may have a critical role in designing therapy and in prognostication for patients with metastatic disease localized to the serosal cavities.
Konstantinovsky
Sophya
S
Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Smith
Yoav
Y
Zilber
Sofia
S
Tuft Stavnes
Helene
H
Becker
Anne-Marie
AM
Nesland
Jahn M
JM
Reich
Reuven
R
Davidson
Ben
B
Hum Pathol. 2008 May;39(5):747-57
18439941
Dev Cell. 2007 Apr;12(4):487-502
17419990
Clin Cancer Res. 2004 Nov 1;10(21):7335-46
15534110
Oncogene. 2006 Oct 16;25(48):6416-22
17041626
Mutat Res. 2008 Mar-Apr;658(3):234-46
18291711
Oncologist. 2007 Nov;12(11):1276-87
18055847
Clin Cancer Res. 2004 Sep 1;10(17):5769-76
15355905
J Biol Chem. 2005 Jun 24;280(25):23516-22
15817476
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63
17911267
J Surg Res. 2009 Mar;152(1):104-10
18394649
Acta Cytol. 1994 Nov-Dec;38(6):945-52
7992584
Cancer Res. 2008 Feb 15;68(4):1162-9
18281492
Drugs. 2001;61(12):1721-33
11693462
Respiration. 1998;65(2):108-13
9580921
Breast Cancer Res Treat. 2004 Jan;83(2):119-28
14997042
Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93
11283726
J Cell Biol. 1998 Oct 19;143(2):391-401
9786950
Growth Factors. 2007 Aug;25(4):209-26
18092230
Oncogene. 2005 Feb 3;24(6):1104-10
15690056
Obstet Gynecol. 2008 Jan;111(1):144-51
18165403
Breast Cancer Res Treat. 2007 Dec;106(3):319-31
17347776
J Cell Biochem. 2006 Sep 1;99(1):35-52
16823799
Jpn J Clin Oncol. 2007 Nov;37(11):820-8
17932113
Eur J Surg Oncol. 1994 Feb;20(1):33-6
8131866
Nat Genet. 1998 Aug;19(4):361-5
9697697
Cancer Lett. 2008 Mar 8;261(1):55-63
18155831
Clin Exp Metastasis. 2007;24(2):69-78
17370041
Am J Clin Pathol. 2007 Sep;128(3):389-97
17709312
Cell Cycle. 2007 Jul 15;6(14):1692-5
17637564
Am J Surg Pathol. 2001 Nov;25(11):1405-12
11684957
Gynecol Oncol. 2006 Sep;102(3):453-61
16494928
Clin Exp Metastasis. 2006;23(3-4):227-36
17028919
J Cell Biol. 2005 Feb 28;168(5):813-24
15728191
Breast Cancer Res Treat. 2009 Mar;114(1):23-30
18351453
Nucleic Acids Res. 2002 Feb 15;30(4):e15
11842121
Semin Oncol. 1985 Mar;12(1):54-75
2579439
Mol Cancer Ther. 2002 Jul;1(9):707-17
12479367
Int J Cancer. 2009 May 1;124(9):2088-97
19142967
Annu Rev Physiol. 2006;68:403-29
16460278
Curr Opin Cell Biol. 2002 Feb;14(1):104-9
11792551
Nat Cell Biol. 2000 May;2(5):281-7
10806479
Cancer Cell. 2005 Dec;8(6):443-54
16338658
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Cancer. 1995 Oct 15;76(8):1377-87
8620412
Prog Biophys Mol Biol. 2003 Jan;81(1):1-44
12475568
Int J Cancer. 2007 Sep 1;121(5):1036-46
17450528